Eovist® & Nephrogenic Systemic Fibrosis

Schmidt & Clark, LLP is No Longer Taking These Cases - If you feel that you may have a potential case, we urge you to contact another law firm adequately suited to handle your case.

Eovist® contrast agents with gadolinium have recently been linked to Nephrogenic Systemic Fibrosis (NSF), also known as Nephrogenic Fibrosing Dermopathy (NFD), a horrible and potentially fatal disease.

What is Eovist?

Eovist is the trade name for gadoxetate disodium, a drug used as a paramagnetic contrast agent during MRI scans marketed by Bayer. MRI stands for Magnetic Resonance Imaging, which is a commonly used medical diagnosis technique in radiology. It uses powerful magnets to differentiate between soft tissues, skeletal and the nervous system. Eovist is given to enhance the MRI image, showing tumors and lesions clearly.

Nephrogenic Systemic Fibrosis (NSF) & Eovist Contrast Dye

NSF is a disease characterized by the hardening of skin and other body tissues as a result of gadolinium contrast agents – such as Eovist – breaking down in the human body. Typically, the skin first begins hardening around the ankles and/or wrists. The disease is progressive. The skin hardening usually then spreads up the legs and arms, and to the torso. Tissue in joints, muscles and internal organs may harden as well, making the disease potentially fatal.

Many health care providers are not familiar with NSF because it is a relatively new disease. The first cases of NSF were identified in 1997, and the first published report of NSF cases appeared in 2000.  The link between NSF and gadolinium was only revealed in 2006. At present, there is no known cure for NSF, and treatments are still in the experimental stage.

Awards & recognition